Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SLN 
Silence Therapeutics PLC (SLN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/17/2025: SLN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $32.37
1 Year Target Price $32.37
| 3 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 189.4% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 07/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 299.91M USD | Price to earnings Ratio - | 1Y Target Price 32.37 |
Price to earnings Ratio - | 1Y Target Price 32.37 | ||
Volume (30-day avg) 7 | Beta 1.41 | 52 Weeks Range 1.97 - 22.46 | Updated Date 07/17/2025 |
52 Weeks Range 1.97 - 22.46 | Updated Date 07/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.53 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -258.21% | Operating Margin (TTM) -18119.72% |
Management Effectiveness
Return on Assets (TTM) -20.96% | Return on Equity (TTM) -53.13% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 90231360 | Price to Sales(TTM) 10.83 |
Enterprise Value 90231360 | Price to Sales(TTM) 10.83 | ||
Enterprise Value to Revenue 3.26 | Enterprise Value to EBITDA -5.78 | Shares Outstanding 47230300 | Shares Floating 76035560 |
Shares Outstanding 47230300 | Shares Floating 76035560 | ||
Percent Insiders 24.38 | Percent Institutions 48.83 |
Upturn AI SWOT
Silence Therapeutics PLC
Company Overview
History and Background
Silence Therapeutics PLC was founded in 1994 and is a UK-based biotechnology company focused on the discovery and development of novel ribonucleic acid interference (RNAi) therapeutics for the treatment of diseases with significant unmet medical needs. Initially focused on gene silencing technologies, it has evolved to focus on specific siRNA (small interfering RNA) therapies.
Core Business Areas
- RNAi Therapeutics: The core business is the development of RNAi therapies, focusing on silencing specific genes to treat diseases. This includes the discovery, development, and clinical testing of siRNA candidates.
- GalNAc Conjugates: Utilizes its proprietary mRNAi GOLDu2122 platform and GalNAc conjugation to deliver siRNA therapeutics to the liver and other tissues.
Leadership and Structure
The leadership team includes the CEO, CFO, CSO, and other key executives. The organizational structure involves departments focused on research and development, clinical trials, regulatory affairs, and commercial strategy.
Top Products and Market Share
Key Offerings
- SLN360: SLN360, targeting lipoprotein(a) (Lp(a)) for cardiovascular risk reduction. The market share of Lp(a) lowering therapies is emerging and difficult to quantify precisely, but significant. Competitors include Novartis (inclisiran) and Amgen, with their own Lp(a) targeting therapies in development.
- SLN124: SLN124, an siRNA targeting TMPRSS6 for the treatment of anemia. There is currently no market share for this product as it is in clinical trials. The competitors include companies developing therapies for anemia associated with iron overload.
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically within RNAi therapeutics, is rapidly evolving. This includes personalized medicine development and expanding targetable diseases.
Positioning
Silence Therapeutics PLC is positioned as a specialist in RNAi therapeutics. Their competitive advantage lies in their mRNAi GOLDu2122 platform technology and GalNAc delivery system, enabling targeted delivery of siRNA.
Total Addressable Market (TAM)
The total addressable market for RNAi therapeutics is estimated to be in the billions of dollars and is expected to grow significantly. Silence Therapeutics PLC is strategically positioned to capture a share of this market with its targeted therapies and proprietary technology.
Upturn SWOT Analysis
Strengths
- Proprietary mRNAi GOLDu2122 platform technology
- Targeted delivery systems
- Strong pipeline of siRNA therapeutics
- Experienced management team
- Strategic partnerships with major pharmaceutical companies
Weaknesses
- Reliance on clinical trial success
- Limited number of approved products
- Cash burn rate associated with R&D
- Competition from larger pharmaceutical companies
- Regulatory hurdles in drug development
Opportunities
- Expanding pipeline with new siRNA targets
- Partnerships with larger pharmaceutical companies for co-development and commercialization
- Advancements in delivery technologies
- Increasing acceptance and adoption of RNAi therapeutics
- Positive clinical trial results to drive investor confidence
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from other RNAi therapeutics companies
- Intellectual property disputes
- Economic downturn impacting investment in biotechnology
Competitors and Market Share
Key Competitors
- ALNY
- REGN
- ARWR
- BNTX
- MRNA
Competitive Landscape
Silence Therapeutics PLC's competitive advantages include its proprietary technology and GalNAc delivery system. Disadvantages include its smaller size and fewer approved products compared to larger pharmaceutical competitors.
Growth Trajectory and Initiatives
Historical Growth: Silence Therapeutics PLC has experienced growth in its pipeline of siRNA therapeutics and has strategic partnerships. Overall growth depends on the clinical trial successes and approval of its products.
Future Projections: Future growth projections are based on the success of its clinical trials and regulatory approvals. Analyst estimates vary, but the consensus view is that Silence Therapeutics PLC has significant growth potential if it brings its products to market.
Recent Initiatives: Recent initiatives include the advancement of its pipeline programs, new partnerships with pharmaceutical companies, and strategic R&D efforts.
Summary
Silence Therapeutics PLC is a biotechnology company focused on RNAi therapeutics and it has shown growth potential based on clinical trial outcomes and partnerships. The strengths of the company lie in its proprietary technology, but it needs to address the challenges related to regulatory approvals and competition. Silence Therapeutics needs to expand its market share within the RNAi therapeutics market. Silence Therapeutics PLC faces threats in the form of trial failures and regulatory setbacks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Estimates
- Public news sources
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company-specific events may impact actual performance.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Silence Therapeutics PLC
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-09-08 | President, CEO & Executive Director Mr. Craig A. Tooman M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 116 | |
Full time employees 116 | |||
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trial for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease. Silence Therapeutics plc has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.